STOCK TITAN

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX) has received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron-containing small molecules for the treatment of tuberculosis (TB) and malaria. The grant supports the discovery of novel inhibitors of aminoacyl-tRNA synthetases using AN2's proprietary boron chemistry platform.

The company aims to combat drug resistance and shorten treatment duration for these infectious diseases, which together cause nearly 2 million deaths per year worldwide. The program focuses on leucyl-tRNA synthetase, a validated human target in Mycobacteria and other bacteria and fungi, with potential applications in TB and nontuberculous Mycobacteria lung disease.

This research builds on AN2's scientific accomplishments in discovering novel leucyl-tRNA synthetase inhibitors, including epetraborole, tavaborole, and ganfeborole.

Positive
  • Received continuation grant from Bill & Melinda Gates Foundation for TB and malaria research
  • Potential to address critical unmet needs in global health therapeutics through non-dilutive funding
  • Builds on previous successes in developing boron-based compounds for infectious diseases
Negative
  • None.

Insights

This grant continuation from the Bill & Melinda Gates Foundation represents a positive development for AN2 Therapeutics, albeit with immediate financial impact. The funding supports the company's efforts to discover novel boron-based therapies for tuberculosis and malaria, two diseases causing nearly 2 million deaths annually.

The focus on aminoacyl-tRNA synthetases, particularly leucyl-tRNA synthetase, as a target is promising. This approach has potential to address unmet needs in antimicrobial treatments, including drug-resistant strains. AN2's boron chemistry platform has already yielded successful compounds like epetraborole and tavaborole, demonstrating its capabilities.

For investors, this grant:

  • Validates AN2's technology and expertise
  • Provides non-dilutive funding for research
  • Could lead to valuable new drug candidates
  • Enhances the company's reputation in infectious disease research

However, it's important to note that drug discovery is a long-term process and immediate revenue impact is unlikely. The market cap of $31,334,553 suggests AN2 is still in early stages, making this type of support important for continued research and development.

Grant from the Bill & Melinda Gates Foundation

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria.

“We are appreciative of the Gates Foundation’s continued support as we advance our joint effort to discover new drugs for tuberculosis and malaria, with the goal of combating drug resistance and shortening treatment duration for these infectious diseases, which together cause nearly 2 million deaths per year worldwide,” said Eric Easom, Co-Founder, President, Chief Executive Officer and Chairman of AN2 Therapeutics. “Our boron chemistry platform and team have a proven history of developing innovative compounds with novel mechanisms of action that address critical unmet needs in infectious diseases and other therapeutic areas. This grant highlights the potential of our boron chemistry platform and supports our commitment to address these critical gaps in global health therapeutics through non-dilutive funding.”

This grant continuation from the foundation will support the discovery of novel inhibitors of aminoacyl-tRNA synthetases using AN2’s proprietary boron chemistry platform to identify new therapies for TB and malaria. Leucyl- tRNA synthetase is a validated human target in Mycobacteria and other bacteria and fungi and has the potential to address significant unmet needs in the antimicrobial space, including TB and nontuberculous Mycobacteria lung disease. This program builds on the scientific accomplishments and expertise of several AN2 scientists who were involved in discovering novel leucyl-tRNA synthetase inhibitors that leverage the power of boron chemistry including epetraborole, (being developed for non-tuberculosis Mycobacteria lung disease or NTM and melioidosis) tavaborole (FDA approved antifungal), and ganfeborole, which is currently in development for tuberculosis by GSK.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, nontuberculous mycobacteria (NTM), and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the potential development of compounds, including novel inhibitors of aminoacyl-tRNA synthetases, for TB and other conditions, development of compounds through boron chemistry research, development of other compounds using our boron chemistry platform, developing compounds leveraging our experience in boron chemistry, and other statements that are not historical fact. These statements are based on AN2’s current estimates, expectations, plans, objectives, and intentions, are not guarantees of future performance, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: future funding by the Gates Foundation and other sources of non-dilutive capital; timely enrollment of patients in AN2’s existing and future clinical trials; AN2’s ability to procure sufficient supply of its product candidates for its existing and future clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with AN2’s product candidates; the significant uncertainty associated with AN2’s product candidates ever receiving any regulatory approvals; AN2’s ability to obtain, maintain, or protect intellectual property rights related to its current and future product candidates; the sufficiency of AN2’s capital resources and need for additional capital to achieve its goals; global macroeconomic conditions and global conflicts; and other risks, including those described under the heading “Risk Factors” in AN2’s reports filed with the U.S. Securities and Exchange Commission (SEC), including AN2’s Quarterly Report on Form 10-Q for the quarters ended March 31 and June 30, 2024. These filings, when made, are available on the investor relations section of AN2’s website at investor.an2therapeutics.com and on the SEC’s website at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law.

COMPANY CONTACT:

Lucy O. Day

Chief Financial Officer

l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:

Anne Bowdidge

ir@an2therapeutics.com

Source: AN2 Therapeutics, Inc.

FAQ

What is the purpose of the grant received by AN2 Therapeutics (ANTX)?

The grant from the Bill & Melinda Gates Foundation is to support AN2 Therapeutics in discovering novel, boron-containing small molecules for the treatment of tuberculosis (TB) and malaria.

What is the focus of AN2 Therapeutics' (ANTX) research using the grant?

AN2 Therapeutics is focusing on discovering novel inhibitors of aminoacyl-tRNA synthetases, specifically leucyl-tRNA synthetase, using their proprietary boron chemistry platform to develop new therapies for TB and malaria.

What are some previous achievements of AN2 Therapeutics (ANTX) in boron-based therapeutics?

AN2 Therapeutics has previously developed boron-based compounds such as epetraborole (for non-tuberculosis Mycobacteria lung disease and melioidosis), tavaborole (FDA-approved antifungal), and ganfeborole (in development for tuberculosis by GSK).

How does the grant support AN2 Therapeutics' (ANTX) business strategy?

The grant provides non-dilutive funding for AN2 Therapeutics to address critical gaps in global health therapeutics, aligning with their commitment to develop innovative compounds for unmet needs in infectious diseases.

AN2 Therapeutics, Inc.

NASDAQ:ANTX

ANTX Rankings

ANTX Latest News

ANTX Stock Data

37.95M
23.21M
21.64%
52.31%
0.45%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MENLO PARK